The Role of PARP in Primary Maintenance of Ovarian Cancer

I tend to stick with either two to three years, favoring closer to two with the regiments that I've described. You mentioned the issue of MDS and AML. What's the latest there, particularly in the primary maintenance setting? The background risk before we utilizing PARP is probably about a half to one percent. But what it also described is that the clinical features outside of Braca in Rad51 CRD was just as good as the molecular, if not better than HRD test negative.